share_log

Top 5 Health Care Stocks That May Surge

Top 5 Health Care Stocks That May Surge

可能飙升的五大医疗保健股
Benzinga Real-time News ·  2023/01/10 07:34

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

医疗保健领域超卖次数最多的股票为买入被低估的公司提供了机会。

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

RSI是一种动量指标，它比较了股票在价格上涨的日子里的强度与价格下跌时的强度。与股票的价格走势相比，它可以让交易者更好地了解股票在短期内的表现。当 RSI 低于 30 时，资产通常被视为超卖。

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

以下是该行业主要超卖参与者的最新名单，RSI接近或低于30。

Vera Therapeutics, Inc. (NASDAQ:VERA)

Vera Therapeutics公司 （纳斯达克股票代码：VERA）

  • Vera Therapeutics recently announced topline results of the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy. The company's stock has a 52-week low of $5.20 .
  • RSI Value: 17.27
  • VERA Price Action: Shares of Vera Therapeutics fell 1.3% to settle at $5.41 on Monday and lost 0.4% in today's pre-market trading.
  • Vera Therapeutics最近公布了阿塔西普治疗IgA肾病的2b ORIGIN期临床试验的主要结果。该公司的股票有 52 周低点 5.20 美元 。
  • RSI 值： 17.27
  • VERA 价格走势： 周一，Vera Therapeutics的股价下跌了1.3％，收于5.41美元，在今天的盘前交易中下跌了0.4％。


Fate Therapeutics, Inc. (NASDAQ:FATE)


Fate Therapeutics, （纳斯达克股票代码：FATE）

  • Goldman Sachs maintained Fate Therapeutics with a Sell and lowered the price target from $10 to $4. The company's stock has a 52-week low of $4.02.
  • RSI Value: 20.46
  • FATE Price Action: Shares of Fate Therapeutics jumped 24.3% to close at $5.27 on Monday and lost 1.9% in today's pre-market trading.
  • 高盛维持了Fate Therapeutics的卖出，并将目标价从10美元下调至4美元。该公司的 股票创下 52 周低点 的 4.02 美元。
  • RSI 值： 20.46
  • FATE 价格走势： 周一，Fate Therapeutics的股价上涨了24.3％，收于5.27美元，在今天的盘前交易中下跌了1.9％。


Century Therapeutics, Inc. (NASDAQ:IPSC)


世纪疗法有限公司 （纳斯达克股票代码：IPSC）

  • Century Therapeutics revealed an internal portfolio prioritization and capital allocation strategy that is expected to extend the cash runway into 2026. The company's stock has a 52-week low of $4.76.
  • RSI Value: 22.67
  • IPSC Price Action: Shares of Century Therapeutics fell 2.9% to close at $4.78 on Monday.
  • Century Therapeutics公布了内部投资组合优先事项和资本配置策略，预计该策略将把现金流延长至2026年。该公司的股票有52周的股票 低点为4.76美元。
  • RSI 值： 22.67
  • IPSC 价格行动： 周一，Century Therapeutics的股价下跌2.9％，收于4.78美元。


Third Harmonic Bio, Inc. (NASDAQ:THRD)


第三谐波生物有限公司 （纳斯达克股票代码：THRD）

  • Morgan Stanley, last month, downgraded Third Harmonic Bio from Overweight to Equal-Weight and lowered the price target from $34 to $5. The company's 52-week low is $3.89.
  • RSI Value: 22.81
  • THRD Price Action: Shares of Third Harmonic Bio closed at $4.20 on Monday.
  • 摩根士丹利，上个月， 降级第三谐波生物 从 “增持” 到 “等重”，并将目标价格从 34 美元下调至 5 美元。该公司的52周低点为3.89美元。
  • RSI 值： 22.81
  • THRD 价格走势： Third Harmonic Bio的股价周一收于4.20美元。


Graphite Bio, Inc. (NASDAQ:GRPH)


石墨生物有限公司 （纳斯达克股票代码：GRPH）

  • Graphite Bio reported it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel.. The company has a 52-week low of $1.59.
  • RSI Value: 26.40
  • GRPH Price Action: Shares of Graphite Bio rose 3.5% to close at $1.9150 on Monday and added 6.5% in today's pre-market trading.
  • Graphite Bio报告说，由于第一位服用nula-cel的患者出现了严重的不良事件，它自愿暂停了针对nulabeglogene autogedtemcel（nula-cel）治疗镰状细胞病的1/2期CEDAR研究。该公司 创下 52 周低点 1.59 美元。
  • RSI 值： 26.40
  • GRPH 价格走势： 周一，Graphite Bio的股价上涨了3.5％，收于1.9150美元，并在今天的盘前交易中上涨了6.5％。

Read More: Insiders Buying Heska, B. Riley Financial And 2 Other Stocks

阅读更多： 内部人士买入 Heska、B. Riley Financial 和其他两只股票

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发